Vectibix Solution
Product Images NDC 55513-954

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Vectibix (NDC 55513-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan Meier Plot Of Overall Survival In Patients With Wild Type Kras Mcrc (study 20080763) (Vectibix 01)

A survival curve graph comparing the proportion alive over time in months for two treatment groups: Panitumumab (n=499) and Cetuximab (n=500). The y-axis shows proportion alive from 0% to 100%, and the x-axis shows time in months up to 36. Panitumumab and Cetuximab survival lines are close, displaying similar survival rates throughout the study period.*

FDA Label Image

Figure 2: Kaplan Meier Plot Of Overall Survival In Patients With Wild Type Ras Mcrc (study 20100007) (Vectibix 02)

A survival curve chart comparing two treatment groups over a 26-month period: panitumumab plus best supportive care (BSC) and BSC alone. The y-axis represents the proportion event-free from 0% to 100%, and the x-axis shows time in months. The chart includes a table of subjects at risk at various time points for each group.*

FDA Label Image

Figure 3: Kaplan Meier Plot Of Overall Survival In Patients With Wild Type Kras Mcrc (study 20050203) (Vectibix 03)

Kaplan-Meier survival curve chart showing the proportion of patients alive over time in months for two treatment groups: Panitumumab plus FOLFOX (n=325) and FOLFOX alone (n=331). The y-axis represents the proportion alive from 0% to 100%, and the x-axis shows time in months from 0 to 72. The chart includes the number of subjects at risk at various time points.*

FDA Label Image

Figure 4: Kaplan Meier Plot Of Overall Survival In Patients With Wild Type Ras Mcrc (study 20050203) (Vectibix 04)

A survival curve plot comparing two treatment groups over time in months: Panitumumab Plus FOLFOX (solid line) versus FOLFOX alone (dotted line). The Y-axis represents the proportion alive (%) ranging from 0 to 100%, and the X-axis shows months from 0 to 72. The number of subjects at risk per group is shown below the X-axis.*

FDA Label Image

Single-dose Vialndc 55513-954-01amgen®vectibix®(panitumumab)injection100 mgeach 5 mL Single-dose Vial Ofvectibix® Contains 100 mgpanitumumab In A Sterile,preservative-free Solution(ph 5.8) Containing 29 mg Sodiumchloride And 34 mg Sodium Acetatein Water For Injection, Usp.store At 2° To 8°c.do Not Freeze Or Shake.protect From Direct Sunlight.rx Only (Vectibix 06)

Vectibix (panitumumab) 100 mg/5 mL Injection single-dose vial label by Amgen, Inc. The label states the vial contains 100 mg panitumumab in sterile, preservative-free solution with sodium chloride and sodium acetate. Storage instructions specify 2° to 8°C, avoiding freezing, shaking, and direct sunlight. Rx only.*

FDA Label Image

Single Use Vialndc 55513-955-01amgen®vectibix®(panitumumab)200 mg200 mg/10 mLinjection For Intravenous Infusionno Preservativestore At 2° To 8°c.do Not Freeze Or Shake.protect From Direct Sunlight.discard Any Unused Portion Of The Vial.rx Only (Vectibix 07)

The label for Vectibix (panitumumab) injection, a single-dose vial containing 400 mg per 20 mL. It is a sterile, preservative-free intravenous solution. The label includes storage instructions to keep between 2° to 8°C, avoid freezing or shaking, and protect from direct sunlight. The product is labeled for prescription use by Amgen, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.